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Timely diagnosis is essential for patients with neurometabolic disorders to
enable targeted treatment. Next-Generation Metabolic Screening (NGMS)
allows for simultaneous screening of multiple diseases and yields a holistic
view of disturbed metabolic pathways. We applied this technique to define a
cerebrospinal fluid (CSF) reference metabolome and validated our approach
with patients with known neurometabolic disorders. Samples were measured
using ultra-high-performance liquid chromatography-quadrupole time-of-
flight mass spectrometry followed by (un)targeted analysis. For the reference
metabolome, CSF samples from patients with normal general chemistry results
and no neurometabolic diagnosis were selected and grouped based on sex and
age (0-2/2-5/5-10/10-15 years). We checked the levels of known biomarkers in
CSF from seven patients with five different neurometabolic disorders to con-
firm the suitability of our method for diagnosis. Untargeted analysis of 87 con-
trol CSF samples yielded 8036 features for semiquantitative analysis. No sex
differences were found, but 1782 features (22%) were different between age
groups (q < 0.05). We identified 206 diagnostic metabolites in targeted analy-
sis. In a subset of 20 high-intensity metabolites and 10 biomarkers, 17 (57%)
were age-dependent. For each neurometabolic patient, ≥1 specific
biomarker(s) could be identified in CSF, thus confirming the diagnosis. In two
cases, age-matching was essential for correct interpretation of the metabolomic
profile. In conclusion, NGMS in CSF is a powerful tool in defining a diagnosis
for neurometabolic disorders. Using our database with many (age-dependent)
features in CSF, our untargeted approach will facilitate biomarker discovery
and further understanding of mechanisms of neurometabolic disorders.
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1 | INTRODUCTION
Neurometabolic disorders are a group of inherited diseases
that mainly affect the central nervous system. Even
though the individual disorders are rare, collectively they
represent an important category of severe but potentially
treatable neurological disorders. The phenotypic manifes-
tation of neurometabolic disorders can be very heteroge-
neous, for example, ranging from epilepsy to movement
disorders to developmental delay. The common theme is
presentation at a (very) young age. Coming to a correct
diagnosis as soon as possible can be life saving for a child,
as specific therapy can only be initiated once the metabolic
defect is identified. Furthermore, understanding of the dis-
turbed metabolic pathways of a disease may also lead to
new opportunities for treatment.
Currently, in parallel to genetic diagnostics, neuro-
metabolic disorders are functionally evaluated by both
imaging techniques (magnetic resonance imaging and
spectroscopy) and biochemical analyses of a limited set of
known (metabolite) biomarkers in body fluids. Specific
metabolic perturbations for neurometabolic diseases can
often only be detected in cerebrospinal fluid (CSF). How-
ever, this strategy prevents the identification of novel dis-
orders affecting unexplored metabolic pathways.
Therefore, there is a need for a more holistic approach to
biochemical diagnostics for neurometabolic disorders. We
recently described such an approach, called Next-
Generation Metabolic Screening (NGMS), applied to
inborn errors of metabolism (IEMs) using plasma sam-
ples.1 This approach comprises metabolomic analysis
using high resolution ultra-high-performance liquid
chromatography-quadrupole time of flight mass spectrom-
etry (UHPLC-QTOF-MS), allowing simultaneous measure-
ment of hundreds of metabolites and diagnosis of more
than 50 IEMs. By extending NGMS to CSF, we now aim to
improve the diagnostic process for patients with neuro-
metabolic diseases and open the way for the discovery of
novel biomarkers and yet unknown metabolic diseases.
As UHPLC-QTOF-MS is a semiquantitative tech-
nique, the detection of deviating metabolites relies on
comparison to controls. Biological and preanalytical vari-
ation within the control group may hamper such compar-
isons. Therefore, we present the metabolomic profile of
control CSF samples obtained from children aged 0 to
15 years (the typical age of presentation for neuro-
metabolic disorders), defining which metabolites can be
identified using NGMS and the degree of variation in
metabolite levels introduced by sex, age, and CSF frac-
tion. Furthermore, we demonstrate the application of
NGMS in CSF for the diagnosis of neurometabolic disor-
ders, taking into account the variation of our control
cohort.
2 | MATERIALS AND METHODS
2.1 | Study population and sample
collection
Controls: leftover CSF samples (storage at −80C)
were selected based on the following criteria:
(a) subject age 0 to 15 years old, (b) collected in 2016,
2017, or 2018, (c) erythrocyte and leukocyte count in
CSF within reference range, (d) if available, routine
CSF parameters hemoglobin, bilirubin, IgG produc-
tion, glucose, lactate and protein within reference
range, and (e) clinical data of the subject, as investi-
gated by a pediatric neurologist, did not suggest the
presence of a disease associated with abnormal CSF
results. In accordance with local legislation, we only
included samples of patients who did not reject to the
anonymized use of their left-over material for valida-
tion purposes. To ensure anonymity, all samples were
labeled with a study number based on sex and age
group (0-2, 2-5, 5-10, 10-15 years old).
To study potential concentration gradients of metabo-
lites, CSF was used from a 6-year-old patient with
increased intracranial pressure of unknown origin
(despite extensive diagnostic work-up). 20 mL of CSF was
withdrawn and divided into four subsequent fractions of
5 mL before storage at −80C.
Patient CSF samples were collected from the local
clinical archive. Informed consent for the use of these
samples for research purposes had been obtained pre-
viously. Diagnoses included isovaleric acidemia (IVA;
OMIM #243500), succinic semialdehyde dehydroge-
nase (SSADH) deficiency (OMIM #271980), N-
acetylneuraminic acid synthase (NANS) deficiency
(OMIM #610442), dihydropyrimidinase (DHP) defi-
ciency (OMIM #222748), and aromatic L-amino acid
decarboxylase (AADC) deficiency (OMIM #608643).
For all diagnoses except the latter, heparin plasma
samples collected on the same date as the respective
CSF sample were included as well. For each patient,
the diagnosis was confirmed on both the genetic and
the metabolic level. Moreover, the patients with NANS
(patient 9)2 and DHP deficiency3 and one of the AADC
deficiency patients (patient 2)4 have previously been
described in detail.
SYNOPSIS
Next-Generation Metabolic Screening in CSF will
facilitate biomarker discovery and further under-
standing of mechanisms of neurometabolic disor-
ders, taking age-dependency into account.
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2.2 | Sample preparation and UHPLC-
QTOF-MS analysis
CSF samples were analyzed by the reversed-phase
UHPLC-QTOF-MS method previously described in detail
for heparin-anticoagulated plasma,1 with some minor
adjustments. For the positive ionization mode, an injec-
tion volume of 1.0 μL rather than 2.0 μL was used. All
analytical batches included a quality control
(QC) sample, a random patient pool (RPP) sample, a pro-
cedure blank (PB) and an internal standard solution. The
QC sample was prepared by pooling 100 μL of the col-
lected samples from the control cohort, while the RPP
sample was made by pooling 30 leftover CSF samples
from patients (age 0-47 years old; 53% male). The pools
were thoroughly mixed, centrifuged and 100 μL aliquots
were stored at −80C. All samples, except the QC, were
measured in duplicate and in antiparallel order; the QC
was measured after each 10 injections. The PB was a
milli-Q water sample prepared in the same way as the
CSF samples.
2.3 | Untargeted analysis of control
cohort
For untargeted analysis, raw data acquired from the
UHPLC-QTOF-MS runs were aligned using the R pack-
age “xcms” (XCMS version 3.4.4 running under R version
3.5.2; see Table S1 for used parameters).5 The extracted
features (ie, the combination of an accurate mass-to-
charge ratio (m/z), retention time (RT) and for each sam-
ple an intensity) were preprocessed by selecting those
within an m/z range of 70 to 700, RT between 0.4 and
16 min, intensity in the PB lower than 10% of the mean
intensity in the control cohort CSF samples, and with an
intensity of ≥10 000 in at least one sample. For semi-
quantitative analyses, we averaged duplicate measure-
ments. In the case of between-run comparisons, we
normalized feature intensities by dividing them by the
average intensity in the pooled QC. Only features for
which the coefficient of variation (CV) in the RPP sample
was ≤20% after normalization were used in these
between-run comparisons.
2.4 | Targeted analysis of IEM-related
metabolites
Annotation was performed using a predefined panel of
322 metabolites known to be associated with IEMs (see
Table S2). Information on established RT of reference
compounds, available for 265 metabolites (82%), was
included in this IEM panel to allow for high confidence
identification according to the guidelines of the Met-
abolomics Standards Initiative.6 Features were identified
based on both m/z and RT of a reference compound (two
orthogonal properties, classified as level 1), or m/z only
(level 2). Features were matched to the IEM panel based
on a <5 ppm deviation for mass accuracy and a <10% rel-
ative RT difference from the reference compound mea-
surement (if available). Of note, only [M+H]+ and [M
+Na]+ adducts for the positive mode and [M−H]− and
[M+Cl]− adducts for the negative mode were included in
this annotation. Initially, we matched features from the
XCMS list obtained in untargeted analysis. In case a
metabolite was not found, Agilent MassHunter Personal
Compound Database and Library Manager Software ver-
sion B.04.00, build 92.0 was used to further check its pres-
ence in the raw data. The 20 metabolites with the highest
signal intensity as well as 10 metabolites that served as
biomarkers for our patient samples (see section 2.5) were
selected for semiquantitative analysis.
We studied the literature to identify metabolites with
known concentration gradients in CSF prior to our
study of the influence of the rostrocaudal gradient on
metabolite levels. For each metabolite, matching fea-
tures were identified in the four CSF fractions as
described above.
2.5 | Confirmation of neurometabolic
diagnoses in CSF
We determined the performance of our NGMS method
compared to the targeted amino acid and neurotrans-
mitter assays that are currently used in diagnostics. To
this end, we performed these targeted assays for 10 con-
trol samples from our cohort and one to three patient
samples for six amino acids and four neurotransmitter
metabolites. Amino acid analysis in CSF was performed
using ion-exchange chromatography on an amino acid
analyzer (Biochrom 30, Biochrom, Cambourne, UK)
according to the procedure recommended by the manu-
facturer. Neurotransmitter metabolites in CSF were
investigated by high-performance liquid chromatogra-
phy with fluorimetric detection as previously described.4
The resulting quantitative concentrations were com-
pared to the semiquantitative intensities derived
from NGMS.
We then applied NGMS to samples of patients with a
known neurometabolic diagnosis. Features that signifi-
cantly differed from controls and could be annotated
using the IEM panel were selected and checked for
known biomarkers of the respective disease of the
patient.
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2.6 | Statistical analysis
Sex-related differences were tested by Wilcoxon signed-
rank test to all selected features, followed by Benjamini-
Hochberg correction with a false discovery rate (FDR) of
5%. Differences between age groups were tested by a
Kruskal-Wallis test with the same correction. For
targeted analysis, we used the feature with the highest
non-saturated intensity for each metabolite for semiquan-
titative analysis. Of note, the Benjamini-Hochberg correc-
tion is based on the number of comparisons within an
analysis. Therefore, it is less stringent in targeted analysis
(aimed at 30 features) than in untargeted analysis (aimed
at thousands of features). Z-scores were calculated to
assess variation within the control group. For the analysis
of CSF fractions and for comparison of NGMS to targeted
assays, we calculated R2 and the relative beta coefficient
(ie, the beta coefficient divided by the mean; βrel) using
linear regression. All statistics were performed using R
version 3.5.2.
Features significantly different between a single
patient and controls were determined by t tests followed
by Bonferroni-Holm correction as described previously.1
The fold change was calculated by dividing the mean
intensity in the patient by the median intensity in the
controls. In case of decreases, the variation between
patient and controls is relatively small compared to the
within-group variation of the controls. Consequently,
such features will not always reach our stringent signifi-
cance threshold. Therefore, all annotated features with a
fold change of ≤−2 were also screened for biomarkers
known to be decreased in the respective disorder. For
age-dependent metabolites, the analysis was repeated
using an age-matched control group.
3 | RESULTS
3.1 | Untargeted analysis of control
cohort
The demographics of the 87 selected control samples are
specified in Table S3. We extracted 39 855 features after
XCMS-based feature detection and alignment (18 751 in
positive mode, and 21 104 in negative mode). After
preprocessing, 13 355 features remained. For further
semiquantitative analysis, the intensities of the
preprocessed features were normalized based on the QC
sample. Those which exceeded a CV of 20% in the RPP
sample after normalization were filtered out, leaving
8036 features. None of these were significantly different
between males and females. 1782 features (22%) signifi-
cantly differed between age groups (q < 0.05).
3.2 | Targeted analysis of IEM-related
metabolites
Features extracted from the control cohort were matched
against a predefined panel (Table S2). This resulted in
detection of 206 metabolites, of which 176 with a level
1 identification. For a subset of 20 high intensity metabo-
lites and 10 biomarkers (indicated in Table S2), semi-
quantitative analysis was performed. Despite less
stringent multiple testing correction, there were still no
metabolites with a significant difference based on sex
(Table S4). However, 17 (57%) of these 30 metabolites
were age-dependent. Figure 1 provides an overview of
the variation for these metabolites, represented by Z-
scores. Figure S1 shows the Z-scores per age group
together with the FDR-corrected P-values for each
metabolite.
We identified 13 metabolites which were previously
reported to exist in a rostrocaudal concentration gradient
in CSF (Table 1), most of which are involved in neuro-
transmitter metabolism. For all metabolites except uric
acid, an increased concentration in the higher fraction
numbers was expected based on the literature, thus a
positive slope (βrel). For 12 of the 13 metabolites, we
found a corresponding feature in the fractions for which
R2 and βrel could be calculated. Figure S2 shows scatter
plots including the linear regression curve for each
metabolite. Several metabolites showed the expected
high correlation among the four fractions, especially
5-hydroxyindoleacetic acid, homovanillic acid, and
methylimidazoleacetic acid.
3.3 | Confirmation of neurometabolic
diagnoses in CSF
We compared semiquantitative intensities from NGMS to
quantitative concentrations from targeted assays for
amino acids (n = 6) and neurotransmitter metabolites
(n = 4) in 13 samples. This generally showed a good cor-
relation (R2 = 0.66-1.00; see Figure S3).
Table 2 lists the findings from our samples of
patients with a known neurometabolic diagnosis. For
each disorder, at least one specific biomarker could
be identified in CSF, confirming the diagnosis. Some
biomarkers had a stronger deviation from controls in
CSF than in plasma (3-hydroxyisovaleric acid, N-
acetylmannosamine), while others had a lower fold
change (isovalerylglycine).
An abnormally low abundance of a metabolite may
not always be significant because the difference between
patient and controls is relatively small when compared to
variation within the control group. However, increases
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are expected to always reach the significance level of
P < .05 (after correction). For two biomarkers, this was
not the case: 3-methoxytyrosine in one AADC deficiency
patient, and 5-hydroxytryptophan in the other. Since the
concentrations of these metabolites were age-dependent
in our control cohort study, the analysis was repeated
using an age-matched control group. In the age-matched
reanalysis, concentrations of both 3-methoxytyrosine and
5-hydroxytryptophan were significantly increased in both
patients (Figure 2).
FIGURE 1 Z-scores of the
20 metabolites with the highest median
intensity (blue) and 10 metabolites that
serve as biomarkers in this study (red)
as measured in 87 control samples.
Boxes show median and second and
third quartiles. Whiskers extend to
minimum and maximum values.
Metabolites with an asterisk (*) are
significantly different between age
groups: see Figure S1 for details
TABLE 1 Metabolites with
concentration gradients in CSF as
identified from literature
Metabolite Reference ID level R2 βrel
3,4-Dihydroxyphenylacetic acid 18 2 0.90 0.071
5-Hydroxyindoleacetic acid 18-20 1 0.97 0.109
5-Hydroxytryptophol 19 2 0.36 −0.040
Creatinine 22 1 0.95 0.014
γ-Aminobutyric acid 23 1 0.51 −0.054
Homocarnosine 23 1 0.48 0.069
Homovanillic acid 18,20 1 0.96 0.125
Hypoxanthine 22 1 0.81 0.031
1-Methylhistamine 21 0 NA NA
Methylimidazoleacetic acid 21 2 0.93 0.188
Uric acid 22 1 0.60 −0.041
Vanylglycol 20 1 0.07 −0.009
Xanthine 22 1 0.81 0.043
Note: The coefficient of determination (R2) and the relative beta coefficient (βrel) were calculated using linear regression. Identification (ID)
levels: 1 = identification based on m/z and RT of a reference compound, 2 = putative identification based on m/z only, 0 = not identified.
NA = not available.
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TABLE 2 Identified biomarkers in samples of patients with a confirmed neurometabolic diagnosis
Diagnosis (OMIM) n Biomarker(s) CSF Plasma
Age-dependent
in CSF?a
Isovaleric acidemia (243500) 1 Isovalerylcarnitine "" "" No (q = 0.52)
Isovalerylglycine "b """ NDd
3-Hydroxyisovaleric acid ##c #c No (q = 0.89)
Succinic semialdehyde dehydrogenase deficiency
(271980)
2 4-Hydroxybutyric acid """/""" """/NA Yes (q = 1.7E−04)
N-acetylneuraminate synthase deficiency (610442) 1 N-acetylmannosamine "" " Yes (q = 7.1E−03)
Dihydropyrimidinase deficiency (222748) 1 Dihydrothymine "" "" Yes (q = 0.017)
Dihydrouracil " " Yes (q = 0.039)
Thymine """ """ NDd
Uracil "b " NDd
Aromatic L-amino acid decarboxylase deficiency
(608643)
2 3-Methoxytyrosine ""/"c NA/NA Yes (q = 6.3E−09)
5-Hydroxytryptophan "c/" NA/NA Yes (q = 6.7E−05)
5-Hydroxyindoleacetic
acid
#c/#c NA/NA Yes (q = 2.5E−10)
Homovanillic acid #c/##c NA/NA Yes (q = 1.5E−07)
Note: Arrows indicate increased (") or decreased (#) intensity of the indicated feature in the patient sample compared with controls. One
arrow: fold change 1-10, two arrows: fold change 10-100, three arrows: fold change >100.
Abbreviations: n, number of patients; NA, not analyzed; ND, not determined.
aBased on q-values (=FDR-adjusted P-values) from the 30 IEM metabolite subanalysis.
bObserved and abnormal in raw data but not observed in aligned data.
cNot selected by standard statistical testing, corrected P-value >.05.
dIntensity in controls is too low for semiquantitative analysis.
FIGURE 2 Analysis of 3-methoxytyrosine and 5-hydroxytryptophan in AADC deficiency patients compared to random and age-
matched controls. Boxplots (blue) represent data from control samples. Boxes show median and second and third quartiles of the control
group. Whiskers extend to minimum and maximum values. Patient samples are individually plotted as points (red/orange). * = Bonferroni
Holm-corrected P-value < .05 (when comparing the single patient to the controls), ns = not significant (P ≥ .05). The figure shows the
relevance of working with age-matched controls
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4 | DISCUSSION
NGMS analysis of 87 control CSF samples from children
aged 0 to 15 years resulted in a reference metabolome
consisting of 8036 features suitable for reproducible,
semiquantitative analysis, including features rep-
resenting 206 metabolites with a known connection to
IEM. Significant differences were apparent between dif-
ferent age groups in both untargeted and targeted analy-
sis. All neurometabolic diagnoses included in this study
could be confirmed based on NGMS measurements in
CSF samples of patients. Of note, for two patients (those
with AADC deficiency), age-matched controls were
required to detect the complete expected biomarker
pattern.
Using XCMS, we initially extracted a total of 39 855
features from our CSF measurements. From our experi-
ence, plasma measurements usually yield approximately
80 000 features. This difference suggests that plasma con-
tains more metabolites than CSF. A possible explanation
is that plasma contains more exogenous metabolites, for
example, metabolites originating from food that do not
reach the CSF. However, biomarker research is usually
aimed at elucidating the endogenous metabolism. Thus,
the use of CSF may be advantageous due to less interfer-
ence by exogenous metabolites that are not of direct
interest. Furthermore, analysis of CSF rather than plasma
is already known to be essential for the biochemical diag-
nosis of some neurometabolic disorders, as is the case
with AADC deficiency.7
Previously, an extensive list of metabolites identified
by “untargeted” metabolomics in CSF of patients aged
0 to 20 years has been published.8 While the use of a
large metabolite library is an advantage when annotating
features, it also means that the analysis is no longer truly
untargeted. Consequently, the discovery of unknown
metabolites is no longer possible. This is also the case for
several published targeted CSF metabolomics
methods.9,10 These can also accurately measure bio-
markers for multiple neurometabolic diagnoses, includ-
ing antiquitin deficiency and AADC deficiency. However,
the main advantage of our method lies in obtaining a full
unannotated dataset. This allows us to zoom in on any
feature that may be divergent in a patient in the future
and perform semiquantitative analyses as showcased for
the IEM panel metabolites in this report. If the feature
cannot be identified using our library or relevant data-
bases (Human Metabolome Database [HMDB],11
Metlin12), additional techniques may be used to elucidate
the molecular structure, for example nuclear magnetic
resonance (NMR) or infrared (IR) ion spectroscopy.2,13,14
To subsequently make a newly identified metabolite bio-
marker available in a diagnostic setting, development of
a targeted assay may be required to provide quantitative,
high-throughput results.
Another study recently also presented an
untargeted metabolomics approach in CSF for diagnosis
of (neuro)metabolic disorders.15 In this study, 1811 mass
peaks were identified, but as signals with unknown iden-
tification were excluded from analysis, comparing this to
our 8036 features is difficult. Furthermore, the methodol-
ogy was based on direct-infusion high-resolution MS,
without prior chromatographic separation. Thus, only
the accurate mass was used to annotate metabolites,
which was done by matching these to the HMDB. How-
ever, the human metabolome comprises many com-
pounds with equal molecular mass that will not be
distinguished in this way. Of note, even when using an
LC system, we found a few pairs of isomers that had the
same retention time and thus could still not be distin-
guished. Therefore, not only a second, but sometimes
even a third orthogonal dimension of information (eg, an
NMR or IR spectrum) is necessary for reliable feature
identification.
As with all metabolomic approaches, we were not
able to get a full coverage of the CSF metabolome. First,
metabolites must be susceptible to ionization and be pre-
sent in sufficiently high concentrations to be detected by
QTOF-MS. Furthermore, detection and (semi-)quantifica-
tion of polar metabolites is limited by the use of a
reversed-phase column. The latter is an obstacle in the
assessment of sugars, which are generally highly polar
and therefore only partially separated. Indeed, in our
study, we were not able to discriminate between glucose
and galactose, as they have the same retention time on
the used column. Such problems may be improved by
also performing measurements using a hydrophilic liquid
interaction chromatography (HILIC) column,16 which
will enhance the retention and separation of polar metab-
olites and thus increase the coverage.
Our results with regard to the effect of sex and age
are in line with daily practice of our diagnostic labora-
tory: while age-dependent reference ranges are applied to
several targeted assays, sex is usually not taken into
account. A previous metabolomic study did find sex dif-
ferences in the concentrations of several metabolites, but
this was in an elderly population.17 Possibly, effects of sex
in metabolism are more pronounced after puberty. Based
on the age-dependent reference ranges, the used age
range of 0 to 2 is relatively wide, as many metabolic
changes occur during the first year of life. This choice is
the consequence of a limited availability of samples
within this range combined with the ethical restriction of
using age groups rather than exact individual ages to pre-
vent identification. However, we believe it would be valu-
able to study the 0 to 2 group in more detail. Future
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studies will therefore be aimed at collecting more CSF,
allowing us to split the samples into narrower subgroups.
Still, it should be noted that acquiring control CSF sam-
ples of this group is a challenge, not only in the present
work, but also for any laboratory dealing with neuro-
metabolic studies. After all, large series of controls are
needed to establish a robust reference that adequately
covers the remarkable changes for some metabolites dur-
ing the first months or years of life.
When metabolites show a concentration gradient in
CSF, the fraction that is used for measurement will influ-
ence the outcome. Therefore, we studied four consecutive
5 mL CSF fractions to confirm the gradient of a
literature-based selection of metabolites. While this
20 mL is only a small amount compared to the total CSF
volume (estimated to be 150 mL in adults), larger
amounts are not relevant for diagnostic purposes: if the
gradient is too subtle to present in the first 20 mL, it will
also not interfere with standard diagnostic testing. More-
over, it is not ethically justified to withdraw a larger vol-
ume because of the elevated risk of post-dural-puncture
headaches. Several metabolites showed a high correlation
among the four fractions, especially
5-hydroxyindoleacetic acid, homovanillic acid, and met-
hylimidazoleacetic acid. This fits with their presumed
concentration gradients.18-21 However, it is hard to draw
definite conclusions with just a single patient and four
samples. We will therefore continue our efforts to collect
fractioned CSF to study concentration gradients in a
larger number of cases. This will allow us to determine
whether to take fraction into account when comparing a
feature of interest between patient and control samples.
As demonstrated by data from the AADC deficiency
patients, knowledge on the age-dependency of metabo-
lites can be vital for making the correct diagnosis. Con-
versely, deviating levels of an age-dependent metabolite
can be mistakenly interpreted as perturbations caused by
the disease if age is not considered when comparing
patients to controls. This may especially apply to very
young patients (<0.5 years old), since several metabolites
appear at much higher level at this age—also demon-
strated by several metabolites with high levels in the 0 to
2 years age group in our study (Figure S1). Therefore,
age-matching should be incorporated in metabolomic
analysis to prevent not only false negative, but also false
positive results.
Our current study shows that NGMS in CSF is a pow-
erful tool for diagnosis of neurometabolic disorders. We
have established a reference CSF metabolome using a
large, well-characterized control CSF cohort. Based on
this reference CSF metabolome, we were able to define
age-dependency of different metabolites. Our validation
study indicates that information on age-dependency can
be crucial for the correct diagnosis of neurometabolic dis-
eases. Now that we have proven the diagnostic power of
NGMS in CSF, this methodology will allow us to extend
this approach to yet unsolved cases with a suspicion of
neurometabolic disease. Untargeted metabolomics will
facilitate biomarker discovery and aid in further under-
standing of disease mechanisms in the brain.
ACKNOWLEDGMENTS
The authors would like to thank Marianne Jonker for her
support in the statistical analysis. The study was funded
by Stofwisselkracht under the project name of “Innova-
tive diagnostics in cerebrospinal fluid of patients with
neurometabolic disorders” (KLM Coene and MM Ver-
beek). The authors confirm independence from the spon-
sor; the content of the article has not been influenced by
the sponsor.
CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.
AUTHOR CONTRIBUTIONS
Tessa M. A. Peters designed and executed the experi-
ments, performed data analysis and interpretation, and
drafted the manuscript. Udo F. H. Engelke contributed to
experimental design, data analysis and data interpreta-
tion, and revised the manuscript. Siebolt de Boer per-
formed analytical measurements, was involved in data
processing and revised the manuscript. Ed van der Heeft
set up and validated the method, aided in analytical mea-
surements, and revised the manuscript. Cynthia Pritsch
selected the samples and revised the manuscript. Purva
Kulkarni wrote the scripts used for data analysis, aided in
data analysis, and revised the manuscript. Ron A. Wevers
contributed to experimental design and revised the man-
uscript. Michèl A. A. P. Willemsen contributed to experi-
mental design, selected the samples, and revised the
manuscript. Marcel M. Verbeek contributed to experi-
mental design, aided in data interpretation, and revised
the manuscript. Karlien L. M. Coene contributed to
experimental design, aided in data interpretation and ini-
tial drafting of the manuscript, and revised the
manuscript.
DATA AVAILABILITY STATEMENT
Data supporting the findings of this study are available as
electronic supplementary material.
ETHICS STATEMENT
All procedures followed were in accordance with the eth-
ical standards of the responsible committee on human
experimentation (institutional and national) and with the
Helsinki Declaration of 1975, as revised in 2000. The
PETERS ET AL. 1119
study has been approved by the Commissie
Mensgebonden Onderzoek Radboudumc under file num-
ber 2016-3011 and titles “Metabolomic characterization
of reference cerebrospinal fluid in children” (for control
samples) and “Metabolomics in cerebrospinal fluid of
patients with known and uncharacterized neuro-
metabolic disorders” (for patient samples). All patients
(or their guardians) approved of the possible use of their
left-over samples for method validation purposes, in
agreement with institutional and national legislation.
This article does not contain any studies with animal sub-
jects performed by the any of the authors.
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SUPPORTING INFORMATION
Additional supporting information may be found online
in the Supporting Information section at the end of this
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